Non-Tyrosine Kinase Inhibitors Market to Witness 9% Annualized Growth, Predicts Roots Analysis

London, United Kingdom, July 16, 2015 --( Roots Analysis has announced the addition of “Non-Tyrosine Kinase Inhibitors in Oncology, 2015-2025” report to their offering. The report provides a comprehensive analysis of the current market landscape and the future outlook of kinase inhibitors not specifically targeting tyrosine kinases. These include kinase inhibitors with activity against serine/threonine kinases, dual specificity kinases or both tyrosine and serine/threonine kinases being developed for oncological indications.

Rupali Verma, the lead analyst, said, “Most of the non-tyrosine kinase inhibitors being developed target mTOR, CDK, RAF and MEK kinases. In addition, there are several novel non-tyrosine kinase inhibitors under development that target other serine/threonine and dual specificity kinases (e.g. PLK1, ERK, PIM, Chk kinases).”

The market currently has seven approved non-tyrosine kinase inhibitors. The report provides in depth insights not only on the approved drugs but also on several other drugs in late stage of development. In fact, one of the key objectives of this report is to understand the future state of the industry. The report forecasts that the market is expected to grow at an annualized rate of ~9% over the next ten years. In addition to Nexavar and Afinitor, there are other drugs with the potential to achieve a blockbuster status; combined with a favourable regulatory regime, the overall opportunity could be significantly higher.

Verma further stated, “Combination therapies are expected to act as the main driver of the market. Several drugs (both marketed and pipeline) are being evaluated as combination therapies. In fact, earlier this year, Ibrance received initial approval as a combination therapy. Another drug, cobimetinib, has been filed for initial NDA as combination therapy.”

Who will benefit from this report?

The research is targeted towards big and small pharma companies involved in the development of non-tyrosine kinase inhibitors for oncology. In particular, you could benefit if you are an:

- Investor
- CXO level decision maker
- R&D manager
- Business Intelligence / Scientific analyst
- Finance manager
- Strategy head

About Roots Analysis

Roots Analysis is a specialist market research company, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector.
Roots Analysis
Arun Gupta